Brought to you by 
SymBio gets rigosertib rights from Onconova
18 Jun 2013
Executive Summary
Onconova Therapeutics Inc. (small-molecule cancer treatments) has granted SymBio Pharmaceuticals Ltd. (therapies for cancer, blood disorders, and autoimmune diseases) exclusive rights to develop and sell the oncology candidate ribosertib (which SymBio will code SyB1101) in Japan and Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SymBio gets rigosertib rights from Onconova
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice